Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double‐blind, placebo‐controlled trial-Reference-Cited by-同舟云学术

Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double‐blind, placebo‐controlled trial

Published:2016-12-24 Issue:2 Volume:65 Page:592-603
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Kimer Nina¹²,Pedersen Julie Steen¹,Busk Troels Malte²,Gluud Lise Lotte¹,Hobolth Lise¹³,Krag Aleksander⁴,Møller Søren²,Bendtsen Flemming¹,

Affiliation:

1. Gastro UnitMedical Division, Copenhagen University HospitalHvidovre Denmark

2. Centre of Functional Imaging and ResearchDepartment of Clinical Physiology and Nuclear Medicine, Copenhagen University HospitalHvidovre Denmark

3. Department of Gastroenterology and HepatologyCopenhagen University HospitalBispebjerg Denmark

4. Department of Gastroenterology and HepatologyOdense University Hospital, and Institute of Clinical ResearchUniversity of Southern Denmark Odense Denmark

Funder

The Research Foundation of The Capital Region of Denmark

Novo Nordisk Foundation

Aase & Ejnar Danielsens Foundation

Amager and Hvidovre Hospital Research Foundation

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.28898

Reference43 articles.

1. Quantitative histological-hemodynamic correlations in cirrhosis

2. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension

3. Vascular endothelial dysfunction in cirrhosis

4. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension

5. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacologic Treatment of Portal Hypertension;Clinics in Liver Disease;2024-08

2. Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation;Journal of Gastroenterology;2024-07-19

3. Pathophysiology and therapeutic options for cirrhotic portal hypertension;The Lancet Gastroenterology & Hepatology;2024-07

4. Low sphingolipid levels predict poor survival in patients with alcohol-related liver disease;JHEP Reports;2024-02

5. Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis;BMC Infectious Diseases;2023-08-28